Yuanyuan Ji, Nassuf Mourdi, Kai Bao, Yuanhao Su, Yongke Wu, Zhishen Ge, Hak Soo Choi, Zhidong Wang
{"title":"Corrigendum to \"Near-infrared fluorescence imaging-guided targeted drug delivery in gastric tumors: From molecular design to clinical translation\" [Adv. Drug Deliv. Rev. 235 (2026) 115891].","authors":"Yuanyuan Ji, Nassuf Mourdi, Kai Bao, Yuanhao Su, Yongke Wu, Zhishen Ge, Hak Soo Choi, Zhidong Wang","doi":"10.1016/j.addr.2026.115962","DOIUrl":"10.1016/j.addr.2026.115962","url":null,"abstract":"","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":" ","pages":"115962"},"PeriodicalIF":21.0,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148928741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anubhav Dhull, Shamila Gopalakrishnan, Anunay James Pulukuri, Anu Rani, Vikrantvir Jain, Rishi Sharma, Anjali Sharma
{"title":"Advances in click-enabled dendrimers: bridging molecular engineering, biomedical applications, and clinical translation.","authors":"Anubhav Dhull, Shamila Gopalakrishnan, Anunay James Pulukuri, Anu Rani, Vikrantvir Jain, Rishi Sharma, Anjali Sharma","doi":"10.1016/j.addr.2026.115997","DOIUrl":"https://doi.org/10.1016/j.addr.2026.115997","url":null,"abstract":"<p><p>Dendrimers are highly branched, multivalent macromolecules with generation-dependent architectures that can be prepared with comparatively well-defined molecular compositions. Their architecture and synthetic tunability enable controlled incorporation of targeting ligands, therapeutic agents, imaging probes, and stimuli-responsive functionalities within a single nanoscale construct. These attributes distinguish dendrimers from many conventional nanocarriers and support their investigation as multifunctional platforms for advanced therapeutic applications. However, broader translation of dendrimer technologies has been hindered by challenges associated with synthetic complexity, manufacturing costs, purification and characterization requirements, large-scale reproducibility, predictable biological performance, and increasingly stringent regulatory expectations for advanced nanomedicines. Click chemistry provides one strategy for addressing some of these synthetic and functionalization limitations by enabling expedited and orthogonal dendrimer construction and further modification. Copper-catalyzed azide-alkyne cycloaddition (CuAAC), strain-promoted azide-alkyne cycloaddition (SPAAC), inverse electron-demand Diels-Alder (IEDDA), thiol-ene, thiol-yne, and related bioorthogonal reactions have expanded the ways in which dendrimers can be synthesized and drugs, targeting ligands, imaging agents, nucleic acids, peptides, proteins, and stimuli-responsive linkers can be incorporated into these scaffolds with greater structural control. This review examines click-enabled dendrimers for various biomedical applications. Emphasis is placed on how dendrimer generation, surface charge, ligand density, linker chemistry, degradability, and click reaction choice influence biological performance and translational potential. Marketed and clinically evaluated dendrimer technologies are also discussed to highlight the design, manufacturing, and characterization requirements needed for broader clinical adoption.</p>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":" ","pages":"115997"},"PeriodicalIF":21.0,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jaehyun Choi, Enzhen Xu, Sihyun Park, Minji Woo, Quoc-Viet Le, Jaiwoo Lee, Yu-Kyoung Oh
{"title":"Toward precision nanomedicine via artificial intelligence guided design and prediction.","authors":"Jaehyun Choi, Enzhen Xu, Sihyun Park, Minji Woo, Quoc-Viet Le, Jaiwoo Lee, Yu-Kyoung Oh","doi":"10.1016/j.addr.2026.115999","DOIUrl":"https://doi.org/10.1016/j.addr.2026.115999","url":null,"abstract":"<p><p>Artificial intelligence (AI) is advancing nanomedicine development by linking formulation variables and biological context with delivery, therapeutic efficacy, and safety. This review examines AI assisted formulation design, centralized formulation databases, prediction of nanoparticle self assembly, and models of cell and tissue selective delivery, biodistribution, and therapeutic outcomes. Recent advances in predicting nanotoxicity and nanoparticle induced immune responses further emphasize the importance of incorporating safety endpoints into nanomedicine optimization. Beyond nanocarrier engineering, foundation models and multimodal analyses of single-cell and spatial data are expanding biological discovery by characterizing disease associated cellular states, prioritizing therapeutic targets, and predicting treatment responses. Computational approaches also support the design of therapeutic RNA, peptides, proteins, and programmable protein nanomaterials. For example, mRNA sequences generated by GEMORNA and delivered via lipid nanoparticles increased erythropoietin expression in mice by up to 15-fold compared with a benchmark sequence. Integration of biological discovery with biomolecular and nanocarrier design may inform therapeutic cargo selection, targeting strategies, and functional nanomaterial development. AI may connect patient specific biological characteristics with predictions of nanomedicine delivery and therapeutic response to support patient stratification and individualized treatment selection. Integration of histological, imaging, molecular, and longitudinal data may enable treatment strategies to be adapted to differences in tissue characteristics, disease state, and therapeutic response. Emerging approaches based on digital twins and adaptive treatment control may extend the framework toward individualized dosing and dynamic treatment optimization. Major challenges include data heterogeneity, limited model generalizability, and the need for experimental and prospective validation. Progress toward precision therapy will require integrated frameworks that jointly consider delivery, efficacy, selectivity, and safety while clearly distinguishing demonstrated applications from future opportunities.</p>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":" ","pages":"115999"},"PeriodicalIF":21.0,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Star polymer nanomedicine: From orthogonal synthetic chemistry to precision in therapeutic interventions.","authors":"A Saini, S Yousefi Adsladabad, A Kakkar","doi":"10.1016/j.addr.2026.115996","DOIUrl":"https://doi.org/10.1016/j.addr.2026.115996","url":null,"abstract":"<p><p>Asymmetric star polymers have offered a viable platform in developing soft nanoparticles for effective therapeutic interventions in high morbidity rate diseases. Orthogonal chemistry has facilitated the construction of such branched polymeric precursors for imparting an advantageous combination of multi-tasking attributes to nanoformulations. Tailoring the overall compositions of nanocarriers is accomplished through sequential independent reactions during or post branched star polymer build-up. This has enabled dispersity which is essential in designing nanomedicine with pre-determined structure-function relationships for specific applications. It has helped expand the scope of nanomedicine through facile development of carriers for small molecule to macromolecule cargo, and their enhanced efficacy in performing multiple complimentary biological tasks. This review brings into focus the elegance of orthogonal chemistry in synthetic articulation of amphiphilic branched star polymer architectures, which is laying the foundation for precision nanomedicine to address complex biological issues. We discuss advantages of strictly controlled asymmetric branched star polymer structure in biomedical applications, and how orthogonal chemistry and star polymer composition offers opportunities in smart formulation development while expediting their bench-to-bedside translation.</p>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":" ","pages":"115996"},"PeriodicalIF":21.0,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bioorthogonal chemistry-enabled multiscale engineering of cancer immunotherapy.","authors":"Weiran Song, Meiling Wang, Shutong Lin, Feng Zhou, Zenan Yang, Feilun Deng, Fangmin Chen, Lingfang Hao, Zhiai Xu, Haijun Yu, Yi Lai","doi":"10.1016/j.addr.2026.115998","DOIUrl":"https://doi.org/10.1016/j.addr.2026.115998","url":null,"abstract":"<p><p>Immunotherapy has revolutionized clinical cancer management by harnessing endogenous or engineered immune responses to eliminate tumors. However, durable and safe responses in many solid tumors remain limited by the difficulty of directing potent immunomodulation to defined tumor lesions, immune-cell interfaces, and lymphoid tissues while avoiding systemic immune-related toxicity. Bioorthogonal chemistry provides a chemical strategy to address this limitation by installing non-native reactive handles in biological systems, where they undergo selective reactions to generate covalent linkages, localized activation, or functional assembly under physiological conditions. In cancer immunotherapy, these reactions can chemically label cells and biomolecules, bridge tumor-immune interfaces, anchor or assemble therapeutic platforms within tumors, and activate immunomodulators at disease-relevant sites. In this review, we first summarize the bioorthogonal reaction principles underlying chemical tagging, covalent ligation, controlled cleavage/decaging, and in situ assembly. We then discuss how these chemistries support multiscale immune engineering, from immune-tumor interface regulation and tumor microenvironment remodeling to antigen-presenting cell programming and lymph node-targeted immune priming. Finally, we highlight current translational progress, remaining challenges, and future directions for clinical implementation of bioorthogonal strategies in cancer immunotherapy. By connecting reaction design with immune-engineering function, this Review provides a framework for understanding bioorthogonal chemistry as a site-confined and multiscale strategy for cancer immunotherapy.</p>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":" ","pages":"115998"},"PeriodicalIF":21.0,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ishaan Duggal, Zachary Warnken, Varsha V Nair, Alan B Watts, Nicholas A Peppas, Hugh D C Smyth
{"title":"Regulatory landscape for inhaled biologics: Considerations and Guidelines.","authors":"Ishaan Duggal, Zachary Warnken, Varsha V Nair, Alan B Watts, Nicholas A Peppas, Hugh D C Smyth","doi":"10.1016/j.addr.2026.115986","DOIUrl":"10.1016/j.addr.2026.115986","url":null,"abstract":"<p><p>Despite significant scientific interest, only a small number of inhaled biologics have reached regulatory approval, reflecting the complex interplay between the inherent structural fragility of biologics during the aerosolization steps intrinsic to inhaled administration and the absence of inhalation-specific regulatory guidance. This review examines the key scientific and technical considerations that influence the stability, safety, and performance of inhaled biologics, including aggregation, chemical degradation, immunogenicity, device compatibility, and the limited availability of inhalation-qualified excipients. Existing regulatory frameworks in the United States and Europe for biological products, inhalation products, and delivery devices provide substantial foundations for inhaled biologic development. Their application requires an integrated assessment of the final formulation-device pairing, particularly where aerosolization alters molecular integrity, biological activity, or pulmonary exposure. This review connects these considerations with clinical experience and proposes a scope for dedicated guidance addressing quality, pulmonary safety, device performance, and clinical benefit. A survey of ongoing clinical trials reveals a growing but constrained pipeline dominated by mRNA therapeutics, protein-based agents, and viral-vectored vaccines, underscoring both progress and persistent formulation barriers. Together, these insights emphasize the urgent need for a harmonized regulatory paradigm tailored to inhaled biologics that integrates biologic-specific analytical expectations, aerosolization stress testing, and clear pathways for excipient qualification.</p>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":" ","pages":"115986"},"PeriodicalIF":21.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yirivinti Hayagreeva Dinakar, Raghu Ganugula, Anil K Sood, M N V Ravi Kumar, Meenakshi Arora
{"title":"From acute intervention to chronic management: biopharmaceutical barriers and advanced formulation strategies for peroral metronomic chemotherapy.","authors":"Yirivinti Hayagreeva Dinakar, Raghu Ganugula, Anil K Sood, M N V Ravi Kumar, Meenakshi Arora","doi":"10.1016/j.addr.2026.115988","DOIUrl":"10.1016/j.addr.2026.115988","url":null,"abstract":"<p><p>Although cancer is a chronic disease, conventional oncology has largely relied on maximum tolerated dose (MTD) chemotherapy to achieve rapid tumor killing. However, the limited specificity of these agents frequently results in substantial systemic toxicity and necessitates prolonged treatment-free intervals that may permit tumor regrowth and therapeutic resistance. Metronomic chemotherapy (MET) has emerged as a promising alternative approach, characterized by continuous or intermittent administration of low-dose chemotherapeutic agents over extended periods (often incorporating scheduled drug-free breaks ranging from daily up to weekly). Rather than relying primarily on direct cytotoxicity, MET exerts anti-tumor effects through repeated anti-angiogenic activity, immune modulation, and alteration of tumor microenvironment (TME), while minimizing treatment-related toxicity. These properties make MET particularly attractive for long-term cancer management. Despite its clinical promise, broader implementation of MET remains constrained by challenges associated with drug delivery and administration. For chronic therapeutic regimens, the peroral route represents the most practical and patient-friendly option, offering improved adherence, reduced healthcare burden, and fewer hospital visits. However, many chemotherapeutic agents possess poor aqueous solubility, limited membrane permeability, and unfavorable pharmacokinetic properties, resulting in inadequate peroral bioavailability. In this review, we discuss the evolving role of MET in cancer treatment, compare available routes of administration, and examine the major biopharmaceutical barriers to effective peroral delivery. We further highlight emerging formulation strategies and advanced drug delivery systems designed to overcome these limitations. Collectively, these advances may facilitate the transition of cancer therapy from an episodic, high-intensity intervention toward a sustainable long-term disease management strategy.</p>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":" ","pages":"115988"},"PeriodicalIF":21.0,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahmad Fahmi Bin Anwar Fadzil, Xingchen Liu, Yu Shrike Zhang, Lifeng Kang
{"title":"Additive manufacturing as a unifying platform across drug discovery, drug delivery, and theranostics","authors":"Ahmad Fahmi Bin Anwar Fadzil, Xingchen Liu, Yu Shrike Zhang, Lifeng Kang","doi":"10.1016/j.addr.2026.115983","DOIUrl":"https://doi.org/10.1016/j.addr.2026.115983","url":null,"abstract":"Additive manufacturing (AM), or three-dimensional (3D) printing, is often described as a fabrication technology for producing objects with controlled geometry. Across pharmaceutical science, AM is evolving from a manufacturing tool into a unifying design framework that can coordinate decisions across drug discovery, drug delivery, and theranostics. In upstream drug discovery, bioprinting enables human-relevant tissue models that better capture disease microenvironments for drug testing. In drug delivery, printed dosage forms and devices allow dose, geometry, composition, and release behavior to be programmed through material and architectural designs. In theranostics, printed platforms can integrate sensing, feedback, and treatment within a single patient-facing system. By examining these areas together, this perspective proposes that the traditional boundaries separating drug testing, formulation, and clinical monitoring are progressively eroded. The common feature across these domains is not simply the use of a 3D printer, but the use of spatial control to encode biological, pharmacological, and diagnostic function into physical structures. Collectively, AM should be viewed not as a peripheral technique within drug development, but as a coordinating platform that can link preclinical discovery, clinical delivery, and real-time therapeutic monitoring.","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":"43 1","pages":""},"PeriodicalIF":16.1,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149274681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cynthia Ezeaniekwe, Natasha Logan, Xiaotong Liu, Cuong Cao
{"title":"Peroxidase-mimicking Nanozymes for Redox Monitoring and Regulation in Cancer Theranostics.","authors":"Cynthia Ezeaniekwe, Natasha Logan, Xiaotong Liu, Cuong Cao","doi":"10.1016/j.addr.2026.115981","DOIUrl":"10.1016/j.addr.2026.115981","url":null,"abstract":"<p><p>Cancer progression is closely associated with dysregulated redox homeostasis, including altered hydrogen peroxide (H₂O₂) metabolism and adaptive antioxidant responses within the tumour microenvironment (TME). These biochemical changes provide opportunities for redox-responsive cancer diagnosis and therapeutic intervention. Peroxidase-mimicking nanozymes have emerged as engineered catalytic materials capable of exploiting H₂O₂-dependent reactions for signal amplification and modulation of oxidative stress. This review critically examines their catalytic mechanisms, structural determinants, and applications in cancer theranostics, with particular emphasis on the relationship between interfacial redox chemistry and biological function. Unlike natural peroxidases with structurally defined catalytic sites, many nanozymes mediate peroxide-dependent reactions through surface-associated redox centres involving electron transfer and reactive intermediate formation. Their tunable composition, morphology, and surface chemistry offer opportunities to tailor catalytic performance for diagnostic and therapeutic applications. By exploiting tumour-associated H₂O₂ availability and local acidity, appropriately designed nanozyme systems may facilitate preferential catalytic activation and amplified diagnostic signals. Therapeutically, peroxidase-like activity can promote oxidative damage in cancer cells, while multifunctional nanozyme platforms may incorporate complementary mechanisms to modulate hypoxia, antioxidant defences, and tumour-associated immune responses. However, catalytic performance and tumour selectivity are strongly influenced by biological matrix effects, tumour heterogeneity, catalyst stability, and potential contributions from dissolved metal species. Distinguishing sustained heterogeneous catalysis from consumptive redox reactions, together with establishing in vivo efficacy, safety, and reproducibility, remains essential for clinical translation. Future developments should therefore prioritise mechanistically validated nanozyme platforms that integrate reliable redox monitoring with controllable therapeutic activity, supporting the development of more effective cancer theranostic strategies.</p>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":" ","pages":"115981"},"PeriodicalIF":21.0,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bioactive nanomedicines for multidrug-resistant colorectal cancer: Actionable mechanisms, emerging particle classes, and translational barriers.","authors":"Milad Rasouli, Fatemeh Babaei, Nadia Fallahhossein, Adeleh Divsalar","doi":"10.1016/j.addr.2026.115957","DOIUrl":"https://doi.org/10.1016/j.addr.2026.115957","url":null,"abstract":"<p><p>Multidrug resistance (MDR) in colorectal cancer (CRC) arises from interacting tumour-cell, pharmacological and microenvironmental programmes that undermine both drug activity and delivery. Chemotherapy-associated MDR is the principal focus of this review, while resistance to targeted therapy and immunotherapy is considered where it directly affects delivery design or patient selection. Bioactive compounds can modulate several resistance pathways, but their translational value is constrained by poor solubility, instability, rapid metabolism and inadequate exposure at resistant lesions. This review critically examines when nanomedicine can make such mechanistic activity pharmacologically and translationally meaningful. We link resistance biology to delivery functions, evaluate bioactive chemosensitiser candidates against human exposure, compare major nanomedicine design strategies, and assess nano-bio interactions, repeat-dose safety, manufacturing and clinical positioning. Across the evidence, three limitations recur. First, concentrations associated with chemosensitisation for curcumin, resveratrol, epigallocatechin gallate and quercetin generally exceed measured human parent-analyte exposure. Second, many resistance claims rely on parental or poorly characterised models, whereas studies combining defined resistance provenance with functional mechanism and exposure confirmation remain uncommon. Third, human studies demonstrate feasibility, tissue exposure or treatment response, but not mechanism-specific reversal of CRC MDR by a bioactive compound or bioactive nanomedicine. Progress therefore depends less on adding new particle classes than on matching a necessary formulation function to a defined resistance or spatial barrier, quantifying active exposure in the relevant compartment, validating mechanism in appropriate models, and integrating repeat-dose safety, scalable manufacturing and biomarker-guided clinical development.</p>","PeriodicalId":7254,"journal":{"name":"Advanced drug delivery reviews","volume":" ","pages":"115957"},"PeriodicalIF":21.0,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}